Is β2-Microglobulin a Hidden Driver of Brain Ageing? A Research Map Says Look Closer

Brain ageing is shaped by interactions between the immune system and the nervous system, yet the molecules linking the two are poorly defined. β2-microglobulin (β2M), long dismissed as a nonspecific marker of immune activation, kidney function, or cancer outcomes, is increasingly proposed as one such link.

This paper is a knowledge-mapping analysis rather than a clinical or laboratory study. It examined the published β2M literature using keyword clustering, co-occurrence structure, and burst detection to see how the field is organised and where attention is growing.

The analysis found that β2M research is highly fragmented. Distinct themes include prognosis in haematologic malignancies, systemic inflammation and cytokine networks, cerebrospinal fluid biomarkers, and neurodegeneration. Based on this structure, the author supports reframing β2M as a cross-context biomarker candidate for the ageing brain, citing emerging mechanistic evidence that it may influence neurogenesis, synaptic function, and cognitive performance.

The central implication is a research agenda. The key question is whether β2M is a causal driver, a circulating ageing signal, or a context-dependent modifier. Priorities include harmonised measurement and reporting, stronger multi-compartment evidence linking peripheral and central β2M, longitudinal brain-ageing endpoints, and study designs that incorporate modifiable lifestyle-related risk factors to improve comparability and translational value.

Caveats: a bibliometric map shows where research has concentrated, not whether the biology is true. It does not test causality or establish clinical thresholds. Because only the abstract was available, details of the dataset, search strategy, and specific trends could not be assessed.